journal article·2015-05

Enhanced anti‐cancer activity by co‐delivery of docetaxel and perifosine with multifunctional nanoparticles via regulation of PI3K/Akt signalling pathway

Jingjing Chen, Xiangyuan Bu, Qi Shen

Micro & Nano Letters· Volume 10· Issue 5
Publisher page

Abstract

Recent researches revealed that phosphoinositide 3‐kinase/protein kinase B (PI3K/Akt) plays an important role in the development of drug resistance, reducing the anti‐tumour activity of cytotoxic drugs, such as docetaxel (DTX). The aim of this reported work has been to evaluate DTX and the PI3K/Akt inhibitor perifosine co‐loaded Fol/R 7 (folate/R 7 ) nanoparticles (NPs) for enhancing anti‐cancer activity. The NPs were evaluated by size, zeta potential and morphology. Then cell viability, cellular uptake and apoptosis were performed in MCF‐7 and MCF‐7/Adr cells. The PI3K/Akt inhibition effect was assessed by western blotting. Compared with other experimental groups, DTX and perifosine loaded Fol/R 7 NPs displayed the highest cytotoxicity, cell uptake and early apoptosis in MCF‐7/Adr cells. Furthermore, the PI3K/Akt inhibition effect was enhanced by the Fol/R 7 NPs compared with the free drug group. The DTX and perifosine co‐loaded Fol/R 7 NPs could be a potential, safe and efficient option for enhancing anti‐cancer activity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: PI3K/AKT/mTOR signaling in cancer · Click Chemistry and Applications · Synthesis and biological activity

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy Shanghai Jiao Tong University 800 Dongchuan Road Shanghai 200240 People's Republic of China

Funding

National Natural Science Foundation of China

References (29)

Show source-provided references
1. 10.3324/haematol.2013.08717110.3324/haematol.2013.087171 ↗
2. 10.6004/jnccn.2013.008610.6004/jnccn.2013.0086 ↗
3. 10.1002/ijc.2876910.1002/ijc.28769 ↗
4. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P‐gp, Bcl‐2 and Bax
5. 10.1002/ijc.2442410.1002/ijc.24424 ↗
6. 10.1158/0008‐5472.CAN‐03‐350010.1158/0008‐5472.CAN‐03‐3500 ↗
7. 10.1186/1476‐4598‐12‐2710.1186/1476‐4598‐12‐27 ↗
8. 10.1016/j.biomaterials.2010.03.06610.1016/j.biomaterials.2010.03.066 ↗
9. 10.1016/j.addr.2009.06.00110.1016/j.addr.2009.06.001 ↗
10. 10.1002/anie.20025065310.1002/anie.200250653 ↗
11. 10.1016/j.cis.2014.08.00110.1016/j.cis.2014.08.001 ↗
12. 10.1016/j.ejps.2012.07.00210.1016/j.ejps.2012.07.002 ↗
13. 10.1021/mp400547u10.1021/mp400547u ↗
14. 10.1016/j.biomaterials.2014.06.04010.1016/j.biomaterials.2014.06.040 ↗
15. 10.1158/0008‐5472.CAN‐12‐378310.1158/0008‐5472.CAN‐12‐3783 ↗
16. 10.1016/j.biomaterials.2012.02.00410.1016/j.biomaterials.2012.02.004 ↗
17. 10.1021/jf001269510.1021/jf0012695 ↗
18. 10.1016/j.biomaterials.2012.05.03510.1016/j.biomaterials.2012.05.035 ↗
19. 10.1016/j.ejpb.2005.12.00510.1016/j.ejpb.2005.12.005 ↗
20. 10.1002/marc.20090087610.1002/marc.200900876 ↗
21. 10.1016/j.regpep.2009.03.00310.1016/j.regpep.2009.03.003 ↗
22. 10.1016/j.addr.2010.03.01110.1016/j.addr.2010.03.011 ↗
23. 10.1158/1535‐7163.MCT‐09‐076310.1158/1535‐7163.MCT‐09‐0763 ↗
24. 10.1038/nrc266410.1038/nrc2664 ↗
25. 10.1517/14728222.2014.92450710.1517/14728222.2014.924507 ↗
26. 10.3816/CBC.2010.s.01410.3816/CBC.2010.s.014 ↗
27. 10.1073/pnas.131859811110.1073/pnas.1318598111 ↗
28. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells
29. 10.1111/bph.1225510.1111/bph.12255 ↗